As litigation against Janssen Pharmaceuticals, manufacturer of bladder pain drug Elmiron, mounts, the FDA has approved a change in the drug’s labeling in the U.S. The label of the drug’s “Warnings” section previously did not list any risks concerning visual impairment; however, labeling must now contain “Retinal Pigmentary Changes.” These changes may manifest as pigmentary …. Read More
Grant & Eisenhofer P.A.
In one of the first cases concerning eye damage related to drug Elmiron, the complaint filed in New Jersey Superior Court alleges failure to warn of the drug’s side effects. Elmiron is a prescription drug widely used to treat a bladder pain condition known as interstitial cystitis. Concerns relating to potentially permanent vision loss and …. Read More